Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Shandong Suncadia Medicine Co: Clinical Trials & FDA Approval Profile

Shandong Suncadia Medicine Co (Global / Institutional) sponsors 40 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 26 active protocols (20 recruiting now), 12 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)181 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Shandong Suncadia Medicine Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)40
Active Pipeline (Recruiting Now)26 (20)
Completed vs Stopped Early12 / 0 (0.0%)
Median Closed Actual Enrollment181 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Shandong Suncadia Medicine Co
Hospital Research SiteLocationShared Protocols
West China Hospital of Sichuan UniversityChengdu, Sichuan2
The first affiliated hospital of Zhengzhou UniversityZhengzhou, Henan2
Hunan Cancer HospitalChangsha, Hunan2

Explore interactive annual charts and M&A subsidiary rollups in the Shandong Suncadia Medicine Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI